• Wegovy contains the active ingredient  semaglutide.
  • It is a revolutionary weight-loss injection that offers a clinically proven approach to managing obesity.
  • It was developed by the pharmaceutical company Novo Nordisk.
  • It is a once-weekly injectable treatment designed to regulate appetite and metabolism, providing a targeted solution for sustainable weight loss.
  • Until recently, healthcare professionals would prescribe semaglutide under the brand name Ozempic (which is licenced to treat type 2 diabetes) ‘off-label’ to treat obesity.
  • However, Semaglutide now has an additional product licence under the brand name Wegovy, which is specifically licenced for the management of overweight and obesity, so off-label use of ozempic is no longer required.
  • Wegovy is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition.